Celyad Oncology SA

Celyad Oncology SAverified

CYAD

Price:

$0.47

Market Cap:

$30.24M

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company's precl...[Read more]

Industry

Biotechnology

IPO Date

2015-06-19

Stock Exchange

NASDAQ

Ticker

CYAD

The PE Ratio as of December 2024 (TTM) for Celyad Oncology SA (CYAD) is -0.32

According to Celyad Oncology SA’s latest financial reports and current stock price. The company's current PE Ratio is -0.32. This represents a change of -37.99% compared to the average of -0.52 of the last 4 quarters.

Celyad Oncology SA (CYAD) Historical PE Ratio (quarterly & annually)

How has CYAD PE Ratio performed in the past?

The mean historical PE Ratio of Celyad Oncology SA over the last ten years is -5.92. The current -0.32 PE Ratio has changed 440.45% with respect to the historical average. Over the past ten years (40 quarters), CYAD's PE Ratio was at its highest in in the December 2020 quarter at 4.78. The PE Ratio was at its lowest in in the June 2012 quarter at -48.98.

Quarterly (TTM)
Annual

Average

-5.92

Median

-5.18

Minimum

-14.20

Maximum

-0.28

Celyad Oncology SA (CYAD) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Celyad Oncology SA PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 325.17%

Maximum Annual PE Ratio = -0.28

Minimum Annual Increase = -86.50%

Minimum Annual PE Ratio = -14.20

Quarterly (TTM)
Annual
YearPE RatioChange
2023-1.19325.17%
2022-0.28-86.50%
2021-2.07-60.77%
2020-5.2724.31%
2019-4.24-16.63%
2018-5.09-13.51%
2017-5.88-16.26%
2016-7.03-50.51%
2015-14.202.09%
2014-13.9163.96%

Celyad Oncology SA (CYAD) Average PE Ratio

How has CYAD PE Ratio performed in the past?

The current PE Ratio of Celyad Oncology SA (CYAD) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-1.18

5-year avg

-2.61

10-year avg

-5.92

Celyad Oncology SA (CYAD) PE Ratio vs. Peers

How is CYAD’s PE Ratio compared to its peers?

Celyad Oncology SA’s PE Ratio is greater than Innate Pharma S.A. (-4.56), less than Addex Therapeutics Ltd (1.05), greater than Aptorum Group Limited (-1.59), greater than Dyadic International, Inc. (-8.11), greater than PMV Pharmaceuticals, Inc. (-1.47), less than Eliem Therapeutics, Inc. (0), less than MediciNova, Inc. (-0.04), greater than Pharvaris N.V. (-7.35), greater than PepGen Inc. (-1.51), less than Pasithea Therapeutics Corp. (0), less than Nutriband Inc. (-0.17), greater than ZIVO Bioscience, Inc. (-6.31), greater than null (-5.50),

Build a custom stock screener for Celyad Oncology SA (CYAD) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Celyad Oncology SA using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Celyad Oncology SA (CYAD) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Celyad Oncology SA or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Celyad Oncology SA's PE Ratio?

How is the PE Ratio calculated for Celyad Oncology SA (CYAD)?

What is the highest PE Ratio for Celyad Oncology SA (CYAD)?

What is the 3-year average PE Ratio for Celyad Oncology SA (CYAD)?

What is the 5-year average PE Ratio for Celyad Oncology SA (CYAD)?

How does the current PE Ratio for Celyad Oncology SA (CYAD) compare to its historical average?